MedDRA preferred term · hearing loss

Deafness: adverse event reports recording this term

25,776 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

25,776
reports recording the term: 0.1% of all reports; 1,598
reports, 12 months to June 2026: 1,686 in the 12 months before; 95.9%
marked serious by the reporter: 57.4% across all reports; 2.5%
record death among outcomes, as reported: 9.1% across all reports

"Deafness" (in plain words, hearing loss) is a MedDRA preferred term recorded in 25,776 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,598 reports recorded it in the 12 months to June 2026, close to the 1,686 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 95.9% are marked serious, 2.5% include death among the outcomes and 15.8% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humira, Enbrel and Methotrexate. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Humira	—	1,444	0.2%
Enbrel	Tumor necrosis factor blocker	766	0.1%
Methotrexate	Folate analog metabolic inhibitor	546	0.3%
Entresto	Angiotensin 2 receptor blocker	449	0.4%
Revlimid	Thalidomide analog	421	0.1%
Xeljanz	Janus kinase inhibitor	410	0.3%
Cisplatin	Platinum-based drug	402	0.6%
Apixaban	Factor Xa inhibitor	331	0.7%
Carboplatin	Platinum-based drug	295	0.3%
Lyrica	—	288	0.2%
Cosentyx	Interleukin-17A antagonist	269	0.2%
Tepezza	—	257	4.7%
Avonex	Interferon beta	254	0.2%
Fosamax	Bisphosphonate	241	0.7%
Arava	Antirheumatic agent	238	0.7%
Skyrizi	Interleukin-23 antagonist	236	0.3%
Aspirin	Nonsteroidal anti-inflammatory drug	228	0.3%
Remicade	Tumor necrosis factor blocker	219	0.1%
Tysabri	Integrin receptor antagonist	216	0.1%
Actemra	Interleukin-6 receptor antagonist	214	0.3%
Lipitor	HMG-CoA reductase inhibitor	211	0.4%
Tecfidera	—	206	0.2%
Cyclophosphamide	Alkylating drug	201	0.1%
Etoposide	Topoisomerase inhibitor	201	0.3%
Ibrance	Kinase inhibitor	199	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Tumor necrosis factor blocker	1,442	0.1%	0.1%
Kinase inhibitor	1,121	0.1%	0%
Nonsteroidal anti-inflammatory drug	1,107	0.2%	0%
Angiotensin 2 receptor blocker	968	0.4%	0.1%
Folate analog metabolic inhibitor	741	0.2%	0.1%
Platinum-based drug	730	0.3%	0.3%
Corticosteroid	709	0.1%	0%
Janus kinase inhibitor	660	0.2%	0.2%
Opioid agonist	583	0.1%	0%
Thalidomide analog	564	0.1%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.7%170

2 to 111.3%338

12 to 170.8%218

18 to 447.9%2,026

45 to 6416.4%4,220

65 to 7412%3,094

75 and over14.1%3,635

Age not given46.8%12,075

Patient sex

Female54%13,925

Male37.2%9,598

Not given8.7%2,253

Grey bar: all 20,646,523 reports in the database. 58.4% of these reports give the United States as the country.

Questions about "Deafness"

What does "Deafness" mean in an adverse event report?

In plain language: hearing loss. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record deafness?

25,776 reports through June 2026 (0.1% of all reports), 1,598 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humira (1,444), Enbrel (766), Methotrexate (546), Entresto (449) and Revlimid (421). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.